Jaguar Health, Inc. Sponsors Pediatric Gastroenterology Conference and MVID Panel in Abu Dhabi

Jaguar Health, Inc. has announced its sponsorship through subsidiary Napo Pharmaceuticals at the 10th Annual Elite Ped-GI Congress, held in Abu Dhabi from May 2-4, 2024. The event will feature a panel focused on microvillus inclusion disease (MVID), an ultra-rare disorder. Additionally, Jaguar's plant-based drug, crofelemer, has received Orphan Drug Designation for MVID and short bowel syndrome (SBS) from both the U.S. FDA and the European Medicines Agency.

The panel discussion, titled "Masterclass in Congenital Diarrhea," will be moderated by Dr. Mohamad Miqdady with contributions from leading MVID treatment experts Dr. Christos Tzivinikos and Dr. Antonella Diamanti. Jaguar anticipates initiating a phase 2 trial for MVID, strengthening their position in addressing rare gastrointestinal disorders.

CEO Lisa Conte highlighted ongoing support for investigational studies of crofelemer for MVID and SBS, with results expected in 2024. These studies aim to foster early patient access to treatment based on clinical trials in the EU and potentially in MENA regions.